Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464620 · ClinicalTrials.gov registry record · Phase 2
Trial of Dasatinib in Advanced Sarcomas
A Phase 2 study, sponsored by Sarcoma Alliance for Research through Collaboration.
- Completed
- Registry status
- Phase 2
- Development phase
- 366
- Enrollment target
NCT00464620 is a Phase 2 study that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 366 participants.
The verdict
NCT00464620, a Phase 2 study, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 366 participants
- Enrollment target
Study Summary
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2007-05 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00464620
The ClinicalTrials.gov registry entry for NCT00464620 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT00464620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00464620 about?
NCT00464620 is a clinical study titled "Trial of Dasatinib in Advanced Sarcomas". This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
What is the current status of trial NCT00464620?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 366 participants. The study started on 2007-05. Estimated completion is 2017-05.
What interventions are being tested in trial NCT00464620?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00464620?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.